Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wilmott

Showing results (61-70 of 162) with videos related to

Pageof 17
Sort By:
The American Journal of Surgical Pathology|April 19, 2022
Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue NeviAndrew J Colebatch, Chandra Adhikari, Russell J Diefenbach, et al.
The Lancet. Oncology|April 1, 2018
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studyGeorgina V Long, Victoria Atkinson, Serigne Lo, et al.
British Journal of Cancer|February 14, 2013
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanomaJ S Wilmott, A M Menzies, L E Haydu, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|January 10, 2017
Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomasRobert V Rawson, Peter A Johansson, Nicholas K Hayward, et al.
Histopathology|May 7, 2016
BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reportingHojabr Kakavand, Emily Walker, Trina Lum, et al.
Plos One|January 29, 2026
A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocolKatina J Selvaraj, Diona L Damian, J Guy Lyons, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic TargetsIsmael A Vergara, Karina Aivazian, Matteo S Carlino, et al.
Pigment Cell & Melanoma Research|December 6, 2014
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trialsJason Madore, Ricardo E Vilain, Alexander M Menzies, et al.
Cancer Research|March 1, 2015
RIP1 Kinase Is an Oncogenic Driver in MelanomaXiao Ying Liu, Fritz Lai, Xu Guang Yan, et al.
Plos One|April 3, 2020
Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma modelKelly J McKelvey, Amanda L Hudson, Ramyashree Prasanna Kumar, et al.
Pageof 17

Showing results (61-70 of 162) with videos related to

Sort By:
Pageof 17
The American Journal of Surgical Pathology|April 19, 2022
Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue NeviAndrew J Colebatch, Chandra Adhikari, Russell J Diefenbach, et al.
The Lancet. Oncology|April 1, 2018
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studyGeorgina V Long, Victoria Atkinson, Serigne Lo, et al.
British Journal of Cancer|February 14, 2013
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanomaJ S Wilmott, A M Menzies, L E Haydu, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|January 10, 2017
Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomasRobert V Rawson, Peter A Johansson, Nicholas K Hayward, et al.
Histopathology|May 7, 2016
BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reportingHojabr Kakavand, Emily Walker, Trina Lum, et al.
Plos One|January 29, 2026
A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocolKatina J Selvaraj, Diona L Damian, J Guy Lyons, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic TargetsIsmael A Vergara, Karina Aivazian, Matteo S Carlino, et al.
Pigment Cell & Melanoma Research|December 6, 2014
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trialsJason Madore, Ricardo E Vilain, Alexander M Menzies, et al.
Cancer Research|March 1, 2015
RIP1 Kinase Is an Oncogenic Driver in MelanomaXiao Ying Liu, Fritz Lai, Xu Guang Yan, et al.
Plos One|April 3, 2020
Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma modelKelly J McKelvey, Amanda L Hudson, Ramyashree Prasanna Kumar, et al.
Pageof 17